Philippines

Population 2018  107 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>591 (332–924)</td>
<td>554 (311–866)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>10 (4.1–19)</td>
<td>9.4 (3.8–17)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>18 (7.7–32)</td>
<td>17 (7.3–30)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>26 (22–30)</td>
<td>24 (20–28)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.6 (0.4–2)</td>
<td>0.57 (0.4–)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases  1.7% (1.1–2.5)
Previously treated cases  16% (19–20)

TB case notifications, 2018

- % tested with rapid diagnostics at time of diagnosis  36%
- % with known HIV status  27%
- % pulmonary  98%
- % bacteriologically confirmedººº  36%
- % children aged 0-14 years  12%
- % women  30%
- % men  58%

Total cases notified  382 543

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018  63% (40–110)
TB patients facing catastrophic total costs, 2017  35% (33–37)
TB case fatality ratio (estimated mortality/estimated incidence), 2018  5% (3–7)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive  1 477  1%
- on antiretroviral therapy  1 350  91%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistanceººº
- New cases  <1%
- Previously treated cases  24%

Laboratory-confirmed cases*  MDR/RR-TB: 7 276, XDR-TB: 52
Patients started on treatment**  MDR/RR-TB: 6 125, XDR-TB: 52

TB/RRTB-TB cases tested for resistance to second-line drugs  2 095

Treatment success rate and cohort size

New and relapse cases registered in 2017  91%  315 923
Previously treated cases, excluding relapse, registered in 2017  82%  9 486
HIV-positive TB cases registered in 2017  83%  1 258
MDR/RR-TB cases started on second-line treatment in 2016  58%  5 071
XDR-TB cases started on second-line treatment in 2016  20%  10

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment  52%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment  9.4% (8.7–10)

TB financing, 2019

National TB budget (US$ millions)  205
Funding source: 12% domestic, 25% international, 63% unfunded

- Ranges represent uncertainty intervals
- MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
- Calculated for pulmonary cases only
- Includes cases with unknown previous TB treatment history
- Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-12-28
Data: www.who.int/tb/data